Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Global Phase 3 registrational study assessing BV100

Next Previous
Trial Profile

Global Phase 3 registrational study assessing BV100

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifabutin (Primary)
  • Indications Bacterial infections; Ventilator associated pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors BioVersys

Most Recent Events

  • 11 Dec 2025 According to a BioVersys AG media release, first patients to be dosed in the coming months and Phase 3 read-out expected in H2 2027.
  • 06 Nov 2025 According to a BioVersys AG media release, mandatory Phase 1 clinical trial in healthy volunteers in China precedes the inclusion of Chinese clinical sites by late 2026 into the single Global Phase 3 registration trial of BV100 in Ventilator Associated Bacterial Pneumonia (VABP). Recruitment in other geographies will start earlier.
  • 02 Jul 2025 According to a BioVersys AG media release, the company remains on track to initiate the Phase 3 trial for our most advanced asset BV100 later this year .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top